Lethal Congenital Glycogen Storage Disease of Heart

Also Known As:

Glycogen Storage Disease of Heart, Lethal Congenital; Glycogen Storage Disease of Heart; Phosphorylase Kinase Deficiency of Heart

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders)

Drugs and Important Biological Agents (IBA) related to Lethal Congenital Glycogen Storage Disease of Heart:

1.	Protein Kinases (Protein Kinase)IBA 01/01/2021 - "Mutations in the PRKAG2 gene encoding the 5' Adenosine Monophosphate-Activated Protein Kinase (AMPK), specifically in its γ2 regulatory subunit, lead to Glycogen storage disease of heart, fetal congenital disorder (PRKAG2 syndrome). "
2.	Adenosine Monophosphate (AMP)IBA 01/01/2021 - "Mutations in the PRKAG2 gene encoding the 5' Adenosine Monophosphate-Activated Protein Kinase (AMPK), specifically in its γ2 regulatory subunit, lead to Glycogen storage disease of heart, fetal congenital disorder (PRKAG2 syndrome). "